Clinical Trial Update: Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial registry update describing a Phase 1/Phase 2 study of the PET radioligand [11C]CPPC as a biomarker of microglial activation in amyotrophic late…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• [11C]CPPC (11C-CPPC)

Snippet

Sponsor: Johns Hopkins University | Conditions: ALS | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING